Neoplastic Risk Assessment in Barrett's Esophagus: How Far Have We Come?

Human Pathology

Volumn 34, Issue 10, 2003, Pages 965-967

  Noffsinger, Amy ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

BARRETT ESOPHAGUS; CANCER RISK; EDITORIAL; ENTERITIS; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; GENETIC ANALYSIS; HELICOBACTER INFECTION; HUMAN; MALIGNANT TRANSFORMATION; PLOIDY; RISK ASSESSMENT;

EID: 0142231956     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.humpath.2003.08.008     Document Type: Editorial

References (26)

1. Cameron AJ: Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esoph 15:106-108, 2002
2. Cameron AJ, Lomboy CT: Barrett's esophagus: Age, prevalence and the extent of columnar epithelium. Gastroenterology 103:1454-1458, 1992
3. Overholt B, Panjehpour M, Tefftellar E, et al: PDT for treatment of early adenocarcinoma in Barrett's oesophagus. Gastrointest Endosc 39:73-76, 1993
4. Prevo LJ, Sanches CA, Galipeau C, et al: p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 59:4784-4787, 1999
5. Reid BJ, Haggitt RC, Rubin CE, et al: Barrett's esophagus: Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 93:1-11, 1987
6. Nakamura T, Nekarda H, Hoelscher AH, et al: Prognostic value of DNA ploidy and c-erB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 73:1785-1794, 1994
7. Hollstein M, Sidransky E, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
8. Rotter V, Prokocimer M: p53 and human malignancies. Adv Cancer Res 57:257-272, 1991
9. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
10. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992
11. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
12. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992
13. Kubba AK, Poole NA, Watson A: Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 44:659-667, 1999
14. Skacel M, Petras RE, Rybicki LA, et al: p53 expression in low-grade dysplasia in Barrett's esophagus: Correlation with interobserver agreement and disease progression. Am J Gastroenterol 97: 2508-2513, 2002
15. Younes M, Ertan A, Lechago LV, et al: p53 protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 42:697-701, 1997
16. Terano A, Morita K, Nakamura T, et al: Barrett's esophagus. J Gastroenterol 37:685-690, 2002
17. Boynton RF, Blount PL, Yin J, et al: Loss of heterozygosity involving the APC and MCC genetic loci occurs in the majority of human esophageal cancers. Proc Natl Acad Sci U S A 89:3385-3388, 1992
18. Jankowski JA, Wright NA, Meltzer SJ, et al: Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154:965-973, 1999
19. Huang Y, Boynton RF, Blount PL, et al: Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52:6525-6530, 1992
20. Barrett MT, Sanchez CA, Galipeau PC, et al: Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13: 1867-1873, 1996
21. Sorsdahl K, Casson AG, Troster M, et al: p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: A prospective study. Cancer Detect Prev 18:179-185, 1994
22. Chatelain D, Flejou JF: High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: Histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch 442: 18-24, 2003
23. Zimmerman KC, Sarbia M, Weber AA, et al: Cyclooxygenase-2 expression in human esophageal carcinomas. Cancer Res 59: 198-204, 1999
24. Flejou J-F, Paraf F, Muzeau F, et al: Expression of c-erB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations. J Clin Pathol 47:23-26, 1994
25. Filipe MI, Jankowski J: Growth factors and oncogenes in Barrett's esophagus and gastric metaplasia. Endoscopy 25:637-641, 1993
26. Al-Kasspooles M, Moore JH, Orringer MB, et al: Amplification and over-expression of the EGFR and erB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54:213-219, 1993